Laurus Labs Ltd (LAURUSLABS) is currently trading at 1,807.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments. The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency. Significant capital investment occurred, with 15% of sales reinvested into expanding manufacturing capabilities, particularly in peptides and fermentation facilities. Laurus Labs reported an impressive 388% increase in net profit for 9M FY26, attributed to improved product mix and operational leverage, leading to expanded EBITDA and gross margins. The company is making strategic moves in biotechnology and advanced therapies, operationalizing gene therapy labs and actively investing in ADC capabilities, positioning itself in transformative health technologies.

Over the past 52 weeks, Laurus Labs Ltd has traded between a low of ₹822.85 and a high of ₹1,870.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Laurus Labs Ltd has a market capitalization of approximately 98,034.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Laurus Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 89.66 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 98,034.25 Cr, Laurus Labs Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Laurus Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Laurus Labs Ltd is 89.66. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations was ₹2,026 crore and EBITDA margin was 31.8%, with EBITDA at ₹644 crore.

The text includes multiple snapshots: one states ₹1,529.2, another lists CMP at ₹1,529.8, and another shows ₹1,454 (-1.81%), likely reflecting different timestamps.

The stock rose 53% in Q1FY27 (April to June 2026), described as its sharpest quarterly rally in five years.

The board meeting to consider the audited financial results is scheduled for July 24, 2026, and the earnings conference call is also set for July 24, 2026 at 5:00 PM IST.